Source:

Press Release

January 18, 2022
1 min read
Save

FDA grants priority review to Enhertu for breast cancer subset

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted priority review to fam-trastuzumab deruxtecan-nxki for treatment of certain patients with advanced breast cancer.

The designation applies to use of the agent by adults with unresectable or metastatic HER2-positive breast cancer who received a prior anti-HER2-based regimen.

 The main entrance of FDA Building 1.
Source: Adobe Stock.

Fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo, AstraZeneca) is a HER2-directed antibody-drug conjugate.

The FDA based the priority review designation on results of the randomized phase 3 DESTINY-Breast03 trial. Results showed fam-trastuzumab deruxtecan-nxki reduced risk for progression or death by 72% (HR = 0.28; 95% CI, 0.22-0.37) compared with ado-trastuzumab emtansine (Kadcyla, Genentech) among patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab (Herceptin, Genentech) and a taxane.

Researchers reported 1-year OS rates of 94.1% in the fam-trastuzumab deruxtecan-nxki group and 85.9% among those treated with ado-trastuzumab emtansine.

The safety profile of the agent appeared consistent with that observed in prior trials. The most common grade 3 or higher drug-related treatment-emergent adverse events among patients who received fam-trastuzumab deruxtecan-nxki included neutropenia (19.1%), thrombocytopenia (7%), leukopenia (6.6%), nausea (6.6%), anemia (5.8%) and fatigue (5.1%).

An independent adjudication committee determined 10.5% of patients developed interstitial lung disease or pneumonitis related to treatment. Researchers reported two grade 3 cases; all others were grade 1 or grade 2.

The FDA previously granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for this indication.

The agent is approved in the United States for treatment of patients with unresectable or metastatic HER2-positive breast cancer who received two or more anti-HER2-based regimens in the metastatic setting. It also is approved for treatment of locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who received a prior trastuzumab regimen.